Low-volume mHSPC (Gleason 9, de novo, 66M) doctors completely divided on chemo. How do you decide?
My father (66M) was diagnosed with metastatic hormone-sensitive prostate cancer 2 months ago and we’re stuck in a situation where every oncologist we consult gives a different opinion on chemotherapy. Looking for real experiences from patients or caregivers who faced this same decision.
His diagnosis:
Gleason 4+5 = 9 (Grade Group 5), de novo presentation (metastatic at first diagnosis)
PSA at diagnosis: 251
PSMA PET-CT: PSMA avid left common iliac and external iliac lymph nodes. PSMA avid sclerotic and marrow-based lesions involving lower lumbar vertebrae, sacrum, and left iliac bone.
No visceral involvement (lungs, liver, brain all clear)
By CHAARTED criteria — this is LOW VOLUME disease (3 bone lesions, no visceral mets)
Current treatment (started June 2026):
ADT(degarelix) + ARPI(abirateron)
4 doctors have said no chemo required in Low Volume cases, 3 Doctors are very keen on chemo saying to strike hard as early as possible
In a huge dilemma of whether to proceed with chemo or not. Please guide!